X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia
Members of X4 Pharmaceuticals management team will present clinical data on 25 patients from this fully enrolled trial and discuss mavorixafors potential to treat broader chronic neutropenia populations beyond its lead indication in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome.
- Members of X4 Pharmaceuticals management team will present clinical data on 25 patients from this fully enrolled trial and discuss mavorixafors potential to treat broader chronic neutropenia populations beyond its lead indication in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome.
- The clinical trial ( NCT04154488 ) is a proof-of-concept Phase 1b open-label, multicenter study designed to assess the safety and tolerability of daily, oral mavorixafor with or without G-CSF, in participants with chronic neutropenic disorders including severe congenital, idiopathic, or cyclic neutropenia.
- Participants were dosed with a single dose of oral mavorixafor to assess the magnitude of treatment response.
- X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system.